We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Lab-on-a-Chip Technology Demonstrated in Small Diagnostic Device

By Labmedica staff writers
Posted on 04 Apr 2007
A high sensitivity, small medical diagnostic device was developed using lab-on-a-chip technology. The device can measure biomarkers with high sensitivity and at low cost.

The technology uses semiconductor films located on either side of a microfluidics chip. One film illuminates the chip, where appropriate, while the other film detects an output signal, which is fed to a display. The device used two forms of detection utilizing chemiluminescence and fluorescence to detect different markers of interest.

Developed by Acrongenomics (Geneva, Switzerland) and Molecular Vision (London, UK) this technology is capable of further miniaturization along with large scale, low cost manufacturing, which will bring forward disposable, point-of-care diagnostics for a large range of biomarkers. The companies presented possible design concepts of their BioLED Lab-on-a-Chip technology applications to be used at home, in doctor's offices, and hospitals.

Molecular Vision is a spin-out company of Imperial Innovations Ltd, and was founded in order to meet a clearly defined demand in the medical diagnostics, biosensors, and analytic instrumentations markets: the need for miniaturized chemical and biologic detectors offering high sensitivity and functionality at low cost. The company has directly addressed this market demand by inventing a novel method for optical detection based on recent advances in organic electronics and light-emitting diodes combined with microfluidics technology. The company has mainly focused on applying its technology to the medical diagnostics markets. Molecular Vision recently signed a major development contract with Acrongenomics, Inc., to jointly exploit and commercialize the technology.

Acrongenomics Inc. is a publicly traded company that focuses on investing in and commercializing novel technology platforms concerning the Life Sciences sector. Acrongenomics brings novel and realistic concepts to market by transforming scientific innovations into tangible, consumer-orientated applications.


Related Links:
Acrongenomics

Gold Member
Troponin T QC
Troponin T Quality Control
Automated Blood Typing System
IH-500 NEXT
New
Vibrio Cholerae O1/O139 Rapid Test
StrongStep Vibrio Cholerae O1/O139 Antigen Combo Rapid Test
New
Nuclear Matrix Protein 22 Test
NMP22 Test

Latest Industry News

Bio-Techne and ALZpath Partner to Advance Neurodegenerative Disease Research and Treatment

Microbiologics Acquires Diagnostic Quality Controls Manufacturer SensID

Beckman Coulter Partners with BioPorto for Global Distribution of Acute Kidney Injury NGAL Tests